#Neisseria Gonorrhoeae Infections Treatment Market type
Text
Neisseria Gonorrhoeae Infections Treatment Market 2022 Is Booming Globally | Top Leading Players are Allergan Plc, BioDiem Ltd, Biolytics Pharma, Debiopharm International SA
The Neisseria Gonorrhoeae Infections Treatment Market Size by 2029, exhibiting a CAGR of 4.6% during 2022-2029
Neisseria Gonorrhoeae Infections Treatment Market Overview
The Neisseria Gonorrhoeae Infections Treatment Market report is a comprehensive overview of the market, including a review of its major segments. Neisseria Gonorrhoeae Infections Treatment Market are developed after thorough primary and secondary studies. By speaking with industry experts and collecting their data, in-depth market data is produced. The report provides a thorough account of many market factors, including trends, segmentation, growth prospects, chances, difficulties, and competitive analyses.
Get a Sample copy of the report:
List of Key Players Of Neisseria Gonorrhoeae Infections Treatment Market Report:
Allergan Plc, BioDiem Ltd, Biolytics Pharma, Debiopharm International SA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co., Inc., Paratek Pharmaceuticals, Inc., Recce Pty Ltd, Redx Pharma Plc, Sarepta Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd
Key Segments Covered in Neisseria Gonorrhoeae Infections Treatment Market
By Type, it is segmented into
Cribrostatin-6
Dalbavancin
Debio-1453
Gepotidacin Mesylate
Others
By Application, it is segmented into
Clinic
Hospital
Others
Competitive Landscape
Neisseria Gonorrhoeae Infections Treatment Market are showing an increasing amount of interest in creating unique products. In addition, several companies are collaborating, merging, and acquiring one another. In the upcoming years, all of these initiatives are anticipated to drive the global Neisseria Gonorrhoeae Infections Treatment Market to new heights.
The Neisseria Gonorrhoeae Infections Treatment Market Regional Analysis Covers
– North America: United States, Canada, and Mexico.
– South & Central America: Argentina, Chile, and Brazil.
– Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.
– Europe: UK, France, Italy, Germany, Spain, and Russia.
– Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.
Get in Touch with Us: -
Phone No.+1 (704) 266-3234
Mail to: [email protected]
#Neisseria Gonorrhoeae Infections Treatment Market Research#Neisseria Gonorrhoeae Infections Treatment Market Forecast#Neisseria Gonorrhoeae Infections Treatment Market Size#Neisseria Gonorrhoeae Infections Treatment Market Share#Neisseria Gonorrhoeae Infections Treatment Market Trends#Neisseria Gonorrhoeae Infections Treatment Market Overview
0 notes
Link
Report Scope:
The Global Neisseria Gonorrhoeae Infections Treatment Market report scope covers the in-depth business analysis considering major market dynamics, forecast parameters, and price trends for the industry growth. The report forecasts market sizing at global, regional and country levels, providing comprehensive outlook of industry trends in each market segments and sub-segments from 2017 to 2024. The market segmentations include
To get a free sample report: https://www.supplydemandmarketresearch.com/home/contact/787766?ref=Sample-and-Brochure&toccode=SDMRPH787766
To get a detailed report: https://www.supplydemandmarketresearch.com/global-neisseria-gonorrhoeae-infections-treatment-market-787766
#Neisseria Gonorrhoeae Infections Treatment Market#Neisseria Gonorrhoeae Infections Treatment Market type#Neisseria Gonorrhoeae Infections Treatment Market demand#Neisseria Gonorrhoeae Infections Treatment Market report#Neisseria Gonorrhoeae Infections Treatment Market supply
0 notes
Link
0 notes
Text
Global Antibiotic Resistance Market Growth, Current Status and Future Scenario of Industry Surveyed in New Research Report 2021-2030
Absolute Markets Insights has announced a statistical data to its extensive repository titled Antibiotic Resistance market. The study comprises of different segments and sub-segments such as type, size, applications, and end-users. One of the many distinctive features of the report is it provides an analytical study of the global Antibiotic Resistance market based on various growth influencing factors. Primary and secondary research techniques have also been used by analysts of the report to study the market. The study also uses information on widespread global regions such as North America, Latin America, Europe, Asia-Pacific, Africa, and India in order to get a better understanding of the competitive landscape. The research report extensively focuses on market size, pricing structures, and shares. The current development patterns of various successful industries have also been mentioned in order to understand effective business strategies.
Vendor Profiling: Antibiotic Resistance Market: Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.
For more information about this report visit: https://www.absolutemarketsinsights.com/reports/Antibiotic-Resistance-Market-2021---2029-876
Key Findings of the Report:
The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2030).
The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.
The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.
Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.
Global Antibiotic Resistance Market: Research Scope
By Resistant Bacteria Type
Pseudomonas Aeruginosa
Clostridioides difficile (C. difficile)
Carbapenem-resistant Enterobacteriaceae (CRE)
Streptococcus pneumoniae (S. pneumoniae)
Acinetobacter
Vancomycin-resistant Enterococci (VRE)
Mycobacterium Tuberculosis (TB)
Neisseria gonorrhoeae (N. gonorrhoeae)
Others
By Disease Indication
Complicated Urinary Tract Infections (cUTI)
Complicated Intra-Abdominal Infections (cIAI)
Community-Acquired Bacterial Pneumonia (CABP)
Acute Skin and Skin Structure Infections (ABSSSI)
Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)
Sepsis
Clostridium Difficile (C. difficile) Infections
Others
By Drug Class
Antimycobacterials
Fluoroquinolones
Oxazolidinones
Tetracyclines
Penicillins
Antifolates
Combination Treatment
Others
By Route of Administration
Oral
Topical
Intramuscular
Intravenous (IV)
By End Use
Home Care
Healthcare Facilities
Others
By Region
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
Website: https://www.absolutemarketsinsights.com/
0 notes
Text
Neisseria Gonorrhoeae Infections Treatment Market Growing Demand 2019 to 2025 | Allergan Plc, BioDiem Ltd, Biolytics Pharma
The Global Neisseria Gonorrhoeae Infections Treatment Market report offers insights about the various factors driving the popularity and its features. A comprehensive analysis collected to provide the latest insights into the Global Neisseria Gonorrhoeae Infections Treatment market's acute features. Neisseria Gonorrhoeae Infections Treatment Market explores the effective study of high-leading players in various sectors of industry such as opportunities, size, growth, technology, demand and trend. Neisseria Gonorrhoeae Infections Treatment also offers market-specific statistics on the state of suppliers, a valuable source of advice, guidance for businesses and those involved in the industry.
DOWNLOAD FREE SAMPLE REPORT at: https://www.researchkraft.com/request-sample/1019288
Key Manufacturers Diagnosis:
Allergan Plc, BioDiem Ltd, Biolytics Pharma, Debiopharm International SA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Paratek Pharmaceuticals Inc., Recce Pty Ltd, Redx Pharma Plc, Sarepta Therapeutics Inc., Sumitomo Dainippon Pharma Co. Ltd
The Market is Segmented by Product Type as Follows:
Cribrostatin-6
Dalbavancin
Debio-1453
Gepotidacin Mesylate
Others
Breakdown Information by Application and Market Share and Growth, Covering:
Clinic
Hospital
Others
Each geographic segment of the market was independently examined with pricing and analysis, distribution, and demand data for geographic market notably:
Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey, GCC Countries
Get it at the Discounted price: https://www.researchkraft.com/check-discount/1019288
The Global Neisseria Gonorrhoeae Infections Treatment Market Research Report is a comprehensive market research report that includes an introduction to new trends that can guide businesses in the industry to understand the market and make the strategies for their business growth. The Neisseria Gonorrhoeae Infections Treatment research report looks at market size, industry share, key growth drivers, major segments, and CAGR. The Neisseria Gonorrhoeae Infections Treatment report will answer questions about current market advances and the competitive scope, opportunities, costs and more. The report also scrutinizes in-depth the key international players on the Neisseria Gonorrhoeae Infections Treatment market.
The latest advancements in the Neisseria Gonorrhoeae Infections Treatment industry and changing market trends are key drivers for huge growth. This study also lists the risk factors that will have a direct impact on the global Neisseria Gonorrhoeae Infections Treatment market in the coming years. The types, applications, and key regions of the revenue-generating Neisseria Gonorrhoeae Infections Treatment are assessed. This business report on Neisseria Gonorrhoeae Infections Treatment also analyzes the top countries with their market potential in those areas.
Highlights of the report:
Scrutinized driver data and restrictions affecting the Neisseria Gonorrhoeae Infections Treatment market's growth.
Provide insights into factors affecting growth in the market. Analyzing the Neisseria Gonorrhoeae Infections Treatment industry based on a variety of factors-price analysis, supply chain analysis, porter analysis of five powers etc.
Detailed analysis of the global Neisseria Gonorrhoeae Infections Treatment market's distribution channels, and consumption patterns.
Comprehensive market player assessment of Neisseria Gonorrhoeae Infections Treatment that includes strengths, weaknesses, opportunities and threats.
Extensive detail on recent Neisseria Gonorrhoeae Infections Treatment R&D ventures across different regions and end-use industries.
Updated insights into trends affecting the growth of the Neisseria Gonorrhoeae Infections Treatment market, including ecological preservation, and regulatory standards.
Enquire more about the report at: https://www.researchkraft.com/send-an-enquiry/1019288
0 notes
Text
Molecular Diagnostics Market 2020 Leading Growth Drivers, Emerging Audience, Emerging Factors, Segments
Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Molecular Diagnostics Market and demographic challenges, showed how it could move forward in the coming years.
Molecular Diagnostics Market Top Vendors
The top vendors in the global molecular diagnostics market include Hologic, Inc. (U.S.), QIAGEN N.V. (the Netherlands), Grifols (Spain), Bio-Rad Laboratories, Inc. (US), Abbott (U.S.), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd. (U.S.), Cepheid (U.S.), BD (U.S.), bioMérieux SA (France), Beckman Coulter Inc. (U.S.), and others.
Molecular Diagnostics Market Outlook
The latest study conducted by Market Research Future (MRFR) envisions a promising future for the global molecular diagnostics market, which is poised to surge at a brilliant CAGR of 9.6% during the forecast period (2017-2023).
Molecular diagnostic tests are highly useful in detecting certain sequences in DNA or RNA, which include single nucleotide polymorphism (SNP), rearrangements, deletions, insertions, as well as others so the disease can be further diagnosed. Such cumulative techniques are used for the analyzation of biological markers at the molecular level, like proteome and genome. Furthermore, such techniques can also be used for diagnosing various infectious diseases, cancer, along with many other conditions, in addition to checking the genetic predisposition to a disease.
Read more news on: https://www.medgadget.com/2020/08/coronavirus-covid-19-impact-on-molecular-diagnostics-market-share-2020-research-report-global-size-upcoming-trends-industry-growth-key-companies-new-developments-demand-in-india.html
Molecular Diagnostics Market Growth Drivers and Key Barriers
The relentlessly expanding geriatric population around the world is expected to render tremendous positive impact on the growth of the molecular diagnostics market over the given timeframe. This is true as aging radically augments the risk of infectious and chronic conditions which can be taken care of better when diagnosed at an initial stage of development. Also, United Nations forecasts that the global geriatric population is set to expand from the value of 962 million in 2017 to 2.1 billion by the year 2050. This drastic increase in the elderly population base coupled with the consequent surge in demand for early and improved diagnostic methods will be highly instrumental in the growth of the molecular diagnostics market in the near future.
In addition, the aging population generally opt for non-hospital settings like home care on account of the comfort factor as well as the economic benefits associated with this kind of setting. This factor leads to the increased need for point of care diagnostic testing that offer rapid and accurate results.
Besides, numerous companies are making immense efforts for developing point of care molecular diagnostic tests in order to widen their customer base and also rise above their current market position. They also enter into partnerships and collaborations with other companies in a bid to soar above the intense competition the market is characterized by. Accelerated demand for point of care molecular diagnostic supports the development of the molecular diagnostics market as well, laying a strong foundation for further expansion of the market size in the foreseeable future. Illustrating the efforts put in by the players, Sona Nanotech Inc., in March 2019, collaborated with a UK medical diagnostics company for developing a highly sensitive point of care diagnostic tests that are highly useful for diagnosing various infectious diseases.
Molecular Diagnostics Market Opportunities
With the alarming rise in the occurrence of sexually transmitted infections (STIs) like Chlamydia trachomatis and Neisseria gonorrhoeae, the frequent need of diagnostics is equally on the rise around the world. Therefore, the demand for molecular diagnostics has been quite decent in the past couple of years. In short, the increasing adoption of molecular diagnostics in the wake of increasing STIs across the globe will present countless growth opportunities to the molecular diagnostics market.
Molecular Diagnostics Market Segmentation
The market for molecular diagnostics is segmented on the basis of techniques, applications and end users.
The various techniques in the global market are Polymerase chain reaction (PCR) and real-time PCR, fluorescence in-situ hybridization, microarray, transcription-mediated amplification, and next-generation sequencing.
Application-wise, the market caters to infectious diseases, oncology, blood screening, genetic testing, pharmacogenomics, human leukocyte antigen typing, coagulation, others.
Lastly, the end users that are mentioned in the report are hospitals, diagnostic laboratories, academics and research institutions.
Molecular Diagnostics Market Regional Outlook
The regional analysis done for the global molecular diagnostics market is for the key regions of America, Asia Pacific, Europe, as well as Middle East & Africa.
Based on the geographical distribution, America has attained the substantial share of the global molecular diagnostics market, with Europe and Asia Pacific right behind. Growing prevalence of chronic diseases along with a number of cancer types, and massive investment in research sector for the treatment of diseases has elevated the market position of molecular diagnostics at a global level. The constant prediction of the ever-increasing range of infectious diseases like HIV and hepatitis contribute to the market expansion in the region. Apart from this, a swelling demand for biomarkers that are used for rapid diagnosis will auger well with the regional market growth in the near future.
Europe is steadily catching up with America, amassing the second largest share of the global market on account of the elevated demand for biomarker test for diagnosing cardiovascular diseases, especially amongst the obese people. The molecular diagnostics market in the region observes strong growth on the back of the accelerated demand for advanced molecular diagnostic products.
However, it is the region of Asia Pacific that has catapulted right among the strong contenders in the global market, by growing at the fastest rate. The strong presence of growing number of low budget hospitals and clinics along with a massive population base has resulted in the lavish growth of the market in Asia Pacific.
Middle East & Africa will be noting a rather restricted growth in the global market because of the lack of awareness among the general mass, as well as due to the limited development of the medical industry.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171
Molecular Diagnostics Industry Developments
February 2019 – Co-Diagnostics, Inc. has recently launched its first multi-disease diagnostic which was built by using their patented CoPrimer design platform. This diagnostic test can be used for dengue, chikungunya and Zika, which was developed to cater to the market demand for a cost-effective and highly-accurate diagnostic tool for all the three diseases.
#Molecular Diagnostics Market#Molecular Diagnostics Market Size#Molecular Diagnostics Market Share#Molecular Diagnostics Market Growth#Molecular Diagnostics Market Trends#Molecular Diagnostics Market Analysis
0 notes
Text
Gram-Negative Bacterial Infection Market to be at Forefront by 2025
Global Gram-Negative Bacterial Infection Market: Snapshot
Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.
Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94
The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.
Global Gram-negative Bacterial Infection: Overview
The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection market. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the gram-negative bacterial infection market.
Get TOC for Detailed Facts and Numbers @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial infection market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, gram-negative bacterial infection market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the gram-negative bacterial infection market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
Read Comprehensive Overview of Report @ https://www.tmrresearch.com/gram-negative-bacterial-infection-market
Highlights of the report:
A detailed analysis of key segments of the market
Recent developments in the market’s competitive landscape
Detailed analysis of market segments up to second or third level of segmentation
Historical, current, and projected future valuation of the market in terms of revenue and/or volume
Key business strategies adopted by influential market vendors
Outline of the regulatory framework surrounding and governing numerous aspects of the market
Growth opportunities in emerging and established markets
Recommendations to market players to stay ahead of the competition
0 notes
Text
Global Molecular Diagnostics Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023
Molecular diagnostic tests are highly useful in detecting certain sequences in DNA or RNA, which include single nucleotide polymorphism (SNP), rearrangements, deletions, insertions, as well as others so the disease can be further diagnosed. Such cumulative techniques are used for the analyzation of biological markers at the molecular level, like proteome and genome. Furthermore, such techniques can also be used for diagnosing various infectious diseases, cancer, along with many other conditions, in addition to checking the genetic predisposition to a disease.
The relentlessly expanding geriatric population around the world is expected to render tremendous positive impact on the growth of the molecular diagnostics market over the given timeframe. This is true as aging radically augments the risk of infectious and chronic conditions which can be taken care of better when diagnosed at an initial stage of development. Also, United Nations forecasts that the global geriatric population is set to expand from the value of 962 million in 2017 to 2.1 billion by the year 2050. This drastic increase in the elderly population base coupled with the consequent surge in demand for early and improved diagnostic methods will be highly instrumental in the growth of the molecular diagnostics market in the near future.
Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1171
Market Opportunities
With the alarming rise in the occurrence of sexually transmitted infections (STIs) like Chlamydia trachomatis and Neisseria gonorrhoeae, the frequent need of diagnostics is equally on the rise around the world. Therefore, the demand for molecular diagnostics has been quite decent in the past couple of years. In short, the increasing adoption of molecular diagnostics in the wake of increasing STIs across the globe will present countless growth opportunities to the molecular diagnostics market.
Key players for Global Molecular Diagnostics Market
The top vendors in the global molecular diagnostics market include Hologic, Inc. (U.S.), QIAGEN N.V. (the Netherlands), Grifols (Spain), Bio-Rad Laboratories, Inc. (US), Abbott (U.S.), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd. (U.S.), Cepheid (U.S.), BD (U.S.), bioMérieux SA (France), Beckman Coulter Inc. (U.S.), and others.
Several companies in the molecular diagnostics market are looking to collaborate with research institutes in order to advance their own product development programs. Recently, EZLife announced a collaboration with the UCLA to expand EGFR lung cancer assay into RUO offerings. Such collaborations are likely to be common among key players in the molecular diagnostics market.
Industry Developments
February 2019 – Co-Diagnostics, Inc. has recently launched its first multi-disease diagnostic which was built by using their patented CoPrimer design platform. This diagnostic test can be used for dengue, chikungunya and Zika, which was developed to cater to the market demand for a cost-effective and highly-accurate diagnostic tool for all the three diseases.
Segmental Analysis:
The market for molecular diagnostics is segmented on the basis of techniques, applications and end users.
The various techniques in the global market are Polymerase chain reaction (PCR) and real-time PCR, fluorescence in-situ hybridization, microarray, transcription-mediated amplification, and next-generation sequencing.
Application-wise, the market caters to infectious diseases, oncology, blood screening, genetic testing, pharmacogenomics, human leukocyte antigen typing, coagulation, others.
Lastly, the end users that are mentioned in the report are hospitals, diagnostic laboratories, academics and research institutions.
Regional Analysis:
The regional analysis done for the global molecular diagnostics market is for the key regions of America, Asia Pacific, Europe, as well as Middle East & Africa.
Based on the geographical distribution, America has attained the substantial share of the global molecular diagnostics market, with Europe and Asia Pacific right behind. Growing prevalence of chronic diseases along with a number of cancer types, and massive investment in research sector for the treatment of diseases has elevated the market position of molecular diagnostics at a global level. The constant prediction of the ever-increasing range of infectious diseases like HIV and hepatitis contribute to the market expansion in the region. Apart from this, a swelling demand for biomarkers that are used for rapid diagnosis will auger well with the regional market growth in the near future.
Europe is steadily catching up with America, amassing the second largest share of the global market on account of the elevated demand for biomarker test for diagnosing cardiovascular diseases, especially amongst the obese people. The molecular diagnostics market in the region observes strong growth on the back of the accelerated demand for advanced molecular diagnostic products.
However, it is the region of Asia Pacific that has catapulted right among the strong contenders in the global market, by growing at the fastest rate. The strong presence of growing number of low budget hospitals and clinics along with a massive population base has resulted in the lavish growth of the market in Asia Pacific.
Middle East & Africa will be noting a rather restricted growth in the global market because of the lack of awareness among the general mass, as well as due to the limited development of the medical industry.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]
0 notes
Text
Gram-negative Bacterial Infection – Review On Trending Challenges 2025
Global Gram-negative Bacterial Infection: Overview
The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection market. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the gram-negative bacterial infection market.
Global Gram-Negative Bacterial Infection Market: Snapshot
Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.
The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.
Order Brochure for more Detailed Information @
https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Request TOC for Facts & Tables @
https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial infection market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, gram-negative bacterial infection market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the gram-negative bacterial infection market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
0 notes
Text
Gram-Negative Bacterial Infection Market : Prime factors anticipated piloting for the estimated period 2017-2025
Global Gram-Negative Bacterial Infection Market: Snapshot
Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.
The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.
Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.
Global Gram-negative Bacterial Infection: Overview
The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.
Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94
The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the market.
Global Gram-negative Bacterial Infection: Infection-type Segmentation
On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.
Read Comprehensive Overview of Report@ https://www.tmrresearch.com/gram-negative-bacterial-infection-market
Global Gram-negative Bacterial Infection: Analysis of Treatment Options
In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.
Global Gram-negative Bacterial Infection: Competitive Landscape
Players in the global gram-negative bacterial market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Email: [email protected]
0 notes
Link
Report Scope:
The Global Neisseria Gonorrhoeae Infections Treatment Market report scope covers the in-depth business analysis considering major market dynamics, forecast parameters, and price trends for the industry growth. The report forecasts market sizing at global, regional and country levels, providing comprehensive outlook of industry trends in each market segments and sub-segments from 2017 to 2024. The market segmentations include
To get a free sample report: https://www.supplydemandmarketresearch.com/home/contact/787766?ref=Sample-and-Brochure&toccode=SDMRPH787766
To get a detailed report: https://www.supplydemandmarketresearch.com/global-neisseria-gonorrhoeae-infections-treatment-market-787766
#Neisseria Gonorrhoeae Infections Treatment Market#Neisseria Gonorrhoeae Infections Treatment Market type#Neisseria Gonorrhoeae Infections Treatment Market research#Neisseria Gonorrhoeae Infections Treatment Market report#Neisseria Gonorrhoeae Infections Treatment Market demand
0 notes
Text
Neisseria Gonorrhoeae Infections Treatment Market Estimated to Flourish at by 2025
Neisseria Gonorrhoeae Infections Treatment Market Estimated to Flourish at by 2025
This report studies the global Neisseria Gonorrhoeae Infections Treatment market status and forecast, categorizes the global Neisseria Gonorrhoeae Infections Treatment market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
The global Neisseria Gonorrhoeae…
View On WordPress
0 notes
Text
Global Antibiotic Resistance Market to Grow at 4% CAGR during 2021-2029
When microbes evolve biological mechanisms that can protect them from elimination by antimicrobial, the danger of antimicrobial resistance (AMR) is visible. AMR are drug-resistant pathogens whose spread is a growing public health concern in many countries. The growth of resistant bacteria usually happens due to overuse of antibiotics, or due to their use being different from what has been prescribed. This renders antibiotics less effective or ineffective. It is believed that by 2050, AMR infections may cause 10 million deaths annually. Increase in hospitalizations and increasing use of antibiotics in COVID-19 treatment are expected to further exacerbate AMR. Hence, the market for antibiotic resistance research and medicines useful for treatment is expected accelerate in the near future.
Tuberculosis (TB) is one of the most dangerous infectious diseases from a single infectious agent and its virus has developed significant antibiotic resistance in the modern times. Multidrug-resistant TB (MDR-TB) is considered a global public health emergency by the World Health Organization. According to 2017 estimates, 465,000 cases of TB were estimated worldwide. 38% people were eligible for MDR/Rifampicin-resistant (RR)-TB. 57% of MDR/RR-TB cases received successful treatment. Mylan has also secured approval from Drugs Controller General of India (DCGI) for Pretomanid, which is useful for treatment for highly drug-resistant forms of tuberculosis. Johnson & Johnson has been in the business of developing and responsibly deploying innovative technologies and treatments to combat the growing threat of AMR on multiple fronts.
Request a sample Copy@
https://www.absolutemarketsinsights.com/request_sample.php?id=876
The major factor driving the growth of global antibiotic resistance market is the growing prevalence of hospital-acquired infections. Antibiotic resistant bacteria can spread from person to person in the community. Implementing precautionary infection control procedures can minimize spread of such bacteria in hospitals. From person to person, usually this infection spreads from contact with either contaminated hands of hospital staff, or contaminated surfaces such as door handles, over-bed tables and call bells. Sometimes it also spreads due to contact with contaminated equipment that includes stethoscopes and blood pressure cuffs.
Strategic investments coupled with favorable initiatives by regulatory authorities showcases significant opportunities for the growth of global antibiotic resistance market over the period of next eight years. The Food and Drug Administration (FDA) of the United States of America (USA) and the Centers for Disease Control (CDC) in USA have launched several initiatives to help address antibiotic resistance. FDA is also encouraging new research into effective diagnostic tests, antibiotic regimens, and vaccines. Under qualified infectious disease product (QIDP) program, which is meant to encourage antibiotic development, FDA has also approved new and innovative antibiotics for resistant infections. Such antibiotics include Arikayce (amikacin liposome inhalation suspension), Baxdela (delafloxacin), Nuzyra (omadacycline), Pretomanid, Recarbrio (cilastatin, imipenem, & relebactam), Xerava (eravacycline), and Xepi (ozenoxacin).
The different variants of the coronoavirus has had severe impact on patients. Increased dosage of antibiotics are being prescribed to COVID patients who developed co-infections (bacterial with coronavirus). Increased investments into research and development initiatives towards adequate treatment of the same is anticipated to propel the growth of global antibiotic resistance market over the forecast period.
Enquiry Before Buying@
https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=876
Key Findings of the Report:
· The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2029).
· The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.
· The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.
· Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.
· In 2020, North America dominated the global antibiotic resistance market. Availability of advanced medical sector, increasing prevalence of infectious diseases, presence of major market players, numerous drug launches in the market, and rising growth in the pharmaceutical sector amongst other factors have contributed towards the region’s highest share. Infectious Diseases Society of America (IDSA) has approved the use of many new drugs that are expected to offer successful treatment against bacteria and viruses that have developed antibiotic resistance.
· Some of the major players operating in the global antibiotic resistance market are Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.
Request for Customization@
https://www.absolutemarketsinsights.com/request_for_customization.php?id=876
Global Antibiotic Resistance Market:
· By Resistant Bacteria Type
o Pseudomonas Aeruginosa
o Clostridioides difficile (C. difficile)
o Carbapenem-resistant Enterobacteriaceae (CRE)
o Streptococcus pneumoniae (S. pneumoniae)
o Acinetobacter
o Vancomycin-resistant Enterococci (VRE)
o Mycobacterium Tuberculosis (TB)
o Neisseria gonorrhoeae (N. gonorrhoeae)
o Others
· By Disease Indication
o Complicated Urinary Tract Infections (cUTI)
o Complicated Intra-Abdominal Infections (cIAI)
o Community-Acquired Bacterial Pneumonia (CABP)
o Acute Skin and Skin Structure Infections (ABSSSI)
o Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)
o Sepsis
o Clostridium Difficile (C. difficile) Infections
o Others
· By Drug Class
o Antimycobacterials
o Fluoroquinolones
o Oxazolidinones
o Tetracyclines
o Penicillins
o Antifolates
o Combination Treatment
o Others
· By Route of Administration
o Oral
o Topical
o Intramuscular
o Intravenous (IV)
· By End Use
o Home Care
o Healthcare Facilities
o Others
· By Region
o North America
§ U.S.
§ Canada
§ Mexico
§ Rest of North America
o Europe
§ France
§ The UK
§ Spain
§ Germany
§ Italy
§ Nordic Countries
· Denmark
· Finland
· Iceland
· Sweden
· Norway
§ Benelux Union
· Belgium
· The Netherlands
· Luxembourg
§ Rest of Europe
o Asia Pacific
§ China
§ Japan
§ India
§ New Zealand
§ Australia
§ South Korea
§ Southeast Asia
· Indonesia
· Thailand
· Malaysia
· Singapore
· Rest of Southeast Asia
§ Rest of Asia Pacific
o Middle East & Africa
§ Saudi Arabia
§ UAE
§ Egypt
§ Kuwait
§ South Africa
§ Rest of Middle East & Africa
o Latin America
§ Brazil
§ Argentina
§ Rest of Latin America
For More Information Click@ https://www.absolutemarketsinsights.com/reports/Antibiotic-Resistance-Market-2021---2029-876
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
The Work Lab,Model Colony, Shivajinagar, Pune, MH, 411016
Website: https://www.absolutemarketsinsights.com/
0 notes
Text
Neisseriaceae Infections Market – Trends and Growth Factors Analysis 2014 to 2020
Bacteria represent the essential class of micro-organisms that play a crucial role in the development of infection of any disease to human being and animal. Bacteria are divided into two types on the basis of gram staining test, namely; gram-positive bacteria and gram-negative bacteria. Neisseria is one of the most important genera of bacteria which form colonies on mucosal surfaces of various animals. Neisseria consists of 11 species, out of which, two are pathogenic and others are harmless. These belong to gram negative class of bacteria, since these species show negative response to gram test.The market of Neisseriaceae infections is segmented on the basis of various bacteria that belongs to the class and diseases associated with them, such as, Acinetobacter, Kingella, Neisseria, Moraxella and Oligella. Neisseria contains bacteria such as N. meningitidis, N. gonorrhoeae, N. sicca, N. flava, N. elongata, N. cinerea and others. Out of which, N. gonorrhoeae causes gonorrhea and N. meningitidis causes septicemia and meningitis. Moraxella catarrhalis causes sinusitis, otitis, and pneumonia in adults.
Read Report Overview: https://www.transparencymarketresearch.com/neisseriaceae-infections-market.html
Kingella kingae causes CNS, urinary and respiratory infections. Moreover, it is segmented on the basis of antibacterial drugs, such as, B-lactum antibiotics (Penicillin), clavulanic acid (Augmentin), aminoglycosides (Streptomycin), glycopeptides (Vancomycin), polypeptides (Bacitracin), rifamycins (Rifampicin), chloramphenicol, tetracycline and many others. In addition, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to growing prevalence of various Neisseriaceae infections and associated disease. However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in the upcoming period, owing to rapidly growing prevalence and awareness about the diseases caused due to Neisseriaceae and their chronic effects.The market is expected to show a steady growth during the forecast period from 2014 – 2020. This growth is expected to be driven by many factors, such as, increasing prevalence of Neisseriaceae infections and extensive R&D practices ongoing globally. In addition, rising prevalence of infection diseases is the most important factor that drives the growth of the market to a higher end.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3572
According to the U.S. Centers for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were reported in the U.S. in 2012, an increase of around 4% compared to 2011. Thus, such rising prevalence of infections is an important growth driver of the market. Further, due to extensive R&D practices, number of drugs and formulations are on the way to enter in the market during the forecast period 2014 – 2020. Some of the important pipeline products include AXD0914, Cribrostatin-6, SM-295291 and SM-369926 amongst numerous others. Additionally, due to increased incidences of homosexuality and bisexuality, the threat of gonorrhea has also increased. These factors are supported by rising awareness about the infections and diseases and increasing medical expenditure. Owing to these, the market is expected to grow at steady rate. On the other hand, factors such as government austerity, high cost of treatment and R&D, and ignorance towards the symptoms may hamper the growth of the market to certain extent.Some of the major players engaged in R&D and commercialization of the products in the market include Basilea Pharmaceuticals Ltd., AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Aphios Corporation, Pfizer, Inc., GSK plc, Theravance, Inc., and Pfizer, Inc. amongst many others.
Request For Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3572
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/
0 notes
Text
Chlamydia Infection Diagnostics and Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Market Outline: Chlamydia Infection Diagnostics and Therapeutics Market
Chlamydia is a sexually transmitted disease (STD) caused by the bacteria Chlamydia trachomatis, and it can be transmitted to baby at birth. Chlamydia infection usually doesn’t have any symptoms but often infected may have symptoms such as genital pain and genital discharge both in men and women. Furthermore, chlamydia infection can cause health complications such as preventing women from getting pregnant or even endangering their pregnancies. Some people may experience pain in lower abdomen, pelvis, testicle or vagina and may also have eye discharge or spotting. Treatment may include antibiotics, anti-inflammatory agents, and hospital stay may be required.
Market Dynamics: Chlamydia Infection Diagnostics and Therapeutics Market
Global chlamydia infection diagnostics and therapeutics market is mainly driven by increase in prevalence of sexually transmitted diseases worldwide. Furthermore, emergence of rapid test and advances in biotechnology are expected to boost the chlamydia infection diagnostics and therapeutics market. In addition, increase in R&D activities towards development of therapeutics for antibiotic-resistant bacteria and initiatives by government and non-government agencies (such as World Health Organization (WHO) to increase awareness about STD’s and their symptoms are expected to bolster the chlamydia diagnostics and therapeutics market during the forecast period. However, high cost of development, stringent regulatory procedures for the approval and bacterial drug resistance is expected to hamper the chlamydia infection diagnostics and therapeutics market.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx
Market Scope: Chlamydia Infection Diagnostics and Therapeutics Market
Global chlamydia infection diagnostics and therapeutics market is segmented into diagnostics, therapeutics type, and end user type
Based on diagnostics, market is segmented into
· Direct Fluorescent Tests
· Nucleic Acid Amplification Tests
· Others
Based on therapeutics, market is segmented into
· Antibiotics
o Tetracyclines
o Macrolides
o Quinolones
o Others
· Others
Based on end user, market is segmented into
· Hospitals and Hospital Pharmacies
· Retail Pharmacies
· Others
Based on geography, market is segmented into
· North America
· Asia Pacific
· Europe
· Middle East and Africa
· Latin America
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/#ulp-c654SbFYO64MsOhu
Market overview: Chlamydia Infection Diagnostics and Therapeutics Market
Global chlamydia infection diagnostics and therapeutics market is growing at significant rates owing to prevalence rate of sexually transmitted diseases. According to World Health Organization (WHO), worldwide, more than one million sexually transmitted infections are acquired every day. Each year, an estimate of 131 million new cases of chlamydia infection are reported. Companies are focusing on the development of the new ways to detect chlamydia infection in initial stages. For instance, in December 2016, F. Hoffmann-La Roche AG launched cobas 6800/8800 systems for detection of Chlamydia trachomatis and Neisseria Gonorrhoea (NG) DNA.
Region Overview: Chlamydia Infection Diagnostics and Therapeutics Market
Geographically, chlamydia infection diagnostics and therapeutics market is segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America market is expected to grow at significant rates owing to well-established healthcare infrastructure, presence of more number of market players and increase in awareness in related to early detection and treatment of sexually transmitted diseases. According to Centre for Disease Control and Prevention (CDC) in 2014, a total number of 1,441,789 chlamydia infections were reported to CDC in 50 states and District of Columbia in the United States. Europe chlamydia infection diagnostics and therapeutics market is expected to grow at notable rates owing to factors such as developed healthcare infrastructure and growing awareness related to STI’s. Asia Pacific market growth is attributed to developing infrastructure and prevalence of the chlamydia sexually transmitted diseases. According to World Health Organization, “Global incidence and prevalence of selected curable sexually transmitted infections – 2008”, in South East Asia region estimated that 8 million adults were infected with Chlamydia in 2008.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/#ulp-14mlyhjMGhVjZqa3
Competition Assessment: Chlamydia Infection Diagnostics and Therapeutics Market
Some of the players in chlamydia infection diagnostics and therapeutics market are Novartis AG (Switzerland), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), The Danaher Corporation (U.S.), Abbott Laboratories (U.S.), bioMérieux (France), Siemens AG (Germany), DiaSorin SpA (Italy), Becton Dickinson and Company (U.S.), and Thermo Fisher Scientific (U.S.)
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market/
0 notes
Link
Infectious Diseases Diagnostics Market Size is anticipated to grow at a 7.90% CAGR from 2016 to 2021 and it is estimated that the global market was valued at USD 14.45 billion in 2016 and is relied upon to achieve USD 21.13 billion by 2021. Infectious disease diagnostics involves various method to check for the presence of foreign antigen/organism with the help of numerous diagnostic tools. Infectious disease conditions are highly widespread in under developed regions owing to the lack of awareness for personal hygiene, minimal health care expenditures, and absence of efficient physician services. Rising cases of infectious diseases in developed economies is further expected to boost the market growth. This has lead vitro diagnostic device manufacturers to invest into emerging economies. These companies are taking efforts to develop and commercialize cost effective tools for the infectious disease diagnosis.
Disease diagnostics are used for confirmation of a disease in form of a quick, precise test result. Being time consuming, disease diagnostics are on a rise. The infectious disease epidemics are spreading worldwide, thereby leading to an increase in demand of diagnostic tests. In addition, the incidences of malaria, flu, AIDS, and other diseases are also on a rise, creating a robust demand for infectious disease diagnostics. With a majority of physicians adopting the evidence-based treatment method, infectious disease diagnostic kits are more likely to gain traction over the forecast period. Several government-funded programs all over the globe are increasingly providing free screening and tests in order to increase awareness, accurately diagnose diseases, and minimize the chances of infection. Such initiatives are anticipated to boost the market growth in the next few years. However, diagnostic kits are expensive and manufacturers still have a poor distribution channel for operating across emerging economies. These two factors are projected to be the key challenges to rapid revenue growth of the global infectious diseases diagnostics market.
View full report @ http://www.marketdataforecast.com/market-reports/infectious-diseases-diagnostics-market-4607/
Infectious Diseases Diagnostics Market Segmentation by Product, Application, Technology and End User. On the basis of Product, it is segmented into Instruments, Reagents, Services, and Software. Consumables accounted for the largest share. On the basis of Application, it is segmented into Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), Methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue) included. Hospital-acquired MRSA infections and human papillomavirus (HPV) are expected to be the fastest-growing market segments in the forecast period. On the basis of technology, it is segmented into PCR, INAAT, DNA Sequencing and Hybridization. Traditional methods are categorized into immunodiagnostics, microscopy, and biochemical characterization. Microarrays and INAAT are projected to witness the highest growth during the forecast period. This noteworthy growth can be accredited to the specificity and an increase in the efficiency of these tests. On the basis of End User, it is segmented into Hospital and Laboratories. Hospital laboratories and reference labs held the largest share in this market segment.
Market Segmentation:
1 Product
1.1 Introduction
1.2 Instruments & Analyzers
1.3 Consumables
1.3.1 Assays and Reagents
1.4 Services & Softwares
1.5 Y-o-Y Growth Analysis, By Product
1.6 Market Attractiveness Analysis, By Product
1.7 Market Share Analysis, By Product
2 Techniques
2.1 Introduction
2.2 Traditional Diagnostic Techniques
2.2.1 Immunodiagnostics
2.2.2 Microscopy
2.2.3 Biochemical Characterization
2.3 Molecular Diagnostics
2.3.1 PCR
2.3.2 INAAT
2.3.2 Hybridization
2.3.3 DNA Sequencing & NGS
2.3.4 Microarray
2.3.5 Others
2.4 Y-o-Y Growth Analysis, By Technique
�� 2.5 Market Attractiveness Analysis, By Technique
2.6 Market Share Analysis, By Technique
3 Applications
3.1 Introduction
3.2 Hepatitis B
3.3 Hepatitis C
3.4 Human Immunodeficiency Virus (HIV)
3.5 Tuberculosis (TB)
3.6 Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG)
3.7 Human papillomavirus (HPV)
3.8 Methicillin-resistant Staphylococcus aureus (MRSA)
3.9 Others
3.10 Y-o-Y Growth Analysis, By Application
3.11 Market Attractiveness Analysis, By Application
3.12 Market Share Analysis, By Application
4 End User
4.1 Introduction
4.2 Hospitals Laboratories
4.3 Physician office Labs
4.4 Academics
4.5 Others
4.6 Y-o-Y Growth Analysis, By End User
4.7 Market Attractiveness Analysis, By End User
4.8 Market Share Analysis, By End User
Get free sample report @ http://www.marketdataforecast.com/market-reports/infectious-diseases-diagnostics-market-4607/request-sample
Infectious Diseases Diagnostics Market geographical segmentation by North America, Europe, Asia-Pacific and Middle East and Africa. North America held the largest share of the IDD market, followed by Europe. Both regions are projected to witness single-digit growth rates during the coming years. Be that as it may, Asia-Pacific is projected to register the highest growth rate in the coming years, due to the high pervasiveness of infectious diseases, and huge investment opportunities due to a growth in healthcare expenditure.
Scope of the report:
Global, regional and country-level analysisand forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Segment-level analysisin terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC)in the market and their impact on shifting market dynamics
Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysisfor analyzing the level of competition and business strategy development
A comprehensive list of key market playersalong with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
Competitive landscape analysislisting out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
Expertly devised analyst overview along with Investment opportunitiesto provide both individuals and organizations a strong financial foothold in the market
Buy now@ http://www.marketdataforecast.com/cart/buy-now/infectious-diseases-diagnostics-market-4607
The major Infectious Diseases Diagnostics Market leaders are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, SBecton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: [email protected]
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
0 notes
Last Seen Blogs
dizrythmia
Dizrythmia
ettyequinox
Equinox
houch
i am a slave to my memes
jeonginshaelmoni
JeonginsHalmeoni
